Elevance Health Inc [ELV] stock prices are up 1.38% to $506.97 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ELV shares have lost -1.44% over the last week, with a monthly amount drifted -1.19%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Elevance Health Inc [NYSE: ELV] stock has seen the most recent analyst activity on March 06, 2024, when Barclays initiated its Overweight rating and assigned the stock a price target of $584. Previously, Wolfe Research downgraded its rating to Peer Perform on July 12, 2023. On April 27, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $571 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $547 on April 21, 2023. RBC Capital Mkts upgraded its rating to a Outperform and raised its price target to $572 on March 28, 2023. BofA Securities upgraded its rating to Buy for this stock on September 09, 2022, and upped its price target to $575. In a note dated August 22, 2022, SVB Leerink upgraded an Outperform rating on this stock and boosted its target price from $490 to $580.
The stock price of Elevance Health Inc [ELV] has been fluctuating between $412.00 and $521.18 over the past year. Currently, Wall Street analysts expect the stock to reach $537.95 within the next 12 months. Elevance Health Inc [NYSE: ELV] shares were valued at $506.97 at the most recent close of the market. An investor can expect a potential return of 6.11% based on the average ELV price forecast.
Analyzing the ELV fundamentals
The Elevance Health Inc [NYSE:ELV] reported sales of 171.34B for trailing twelve months, representing a surge of 6.81%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.16 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 502.42 points at the first support level, and at 497.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 512.77, and for the 2nd resistance point, it is at 518.56.
Ratios To Look Out For
It’s worth pointing out that Elevance Health Inc [NYSE:ELV]’s Current Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 0.69, the price to book ratio is 3.01 and price to earnings (TTM) ratio is 20.14.
Transactions by insiders
Recent insider trading involved Kendrick Charles Morgan JR, EVP & President, Commercial, that happened on Mar 08 ’24 when 2432.0 shares were sold. CAO & Controller, Penczek Ronald W completed a deal on Mar 06 ’24 to sell 916.0 shares. Meanwhile, EVP & Pres Carelon & CarelonRx Haytaian Peter D sold 21095.0 shares on Mar 04 ’24.
